奥维斯
ShopShop

Featured Indication · Pollen Allergy

How the nasal spray platform pulls pollen allergy from hypersensitivity back toward immune tolerance

Pollen allergy is highlighted as a standalone indication because it most clearly expresses the platform logic: precise downregulation of overactive allergic signaling, nasal barrier repair, local immune-threshold reset, and reduced amplification of the neuroimmune reflex loop.
Th2 Elevated
The most characteristic immune-imbalance starting point in pollen allergy
Treg Deficiency
Reduced weighting of the local immune-tolerance braking system
NALT Threshold Drift
Nasal-associated lymphoid tissue misreads mild exposure as high risk
Neural Hypersensitivity + Barrier Fragility
Creates an amplification state where minor stimuli cause major symptoms
Research positioning: The pollen-allergy page is the featured single-disease explanation within the nasal spray section. It is not framed as traditional symptom blocking, but as a platform approach that uses engineered signaling modules and synthetic biology exosome delivery to pull the nasal mucosal immune environment from hypersensitive imbalance toward a low-reactivity, tolerant, lower-relapse state.

Five Core Mechanistic Pathways

Complete mechanism map for pollen allergy

These five pathways cover the full chain from upstream immune imbalance to downstream symptom amplification, which is why pollen allergy is isolated as the featured card on the main page.

01

Immune Rebalancing

Pollen Allergy

Precisely downregulating the overactive Th2 allergic pathway

The core problem is not pollen itself, but the body's tendency to classify otherwise tolerable environmental particles as danger signals requiring intense response. The platform first targets the excessively active Th2 bias and reduces the allergic amplification tendency associated with IL-4 / IL-5 / IL-13 signaling.

Th2 downIL-4 / IL-5 / IL-13Less amplificationWeaker IgE cascade
02

Tolerance Rebuilding

Pollen Allergy

Increasing Treg regulatory weight to pull immunity back into a tolerant range

Simply lowering inflammation is not enough, because the local immune system may still remain in a hyper-alert state. The platform therefore raises Treg-linked tolerance signaling so the nasal mucosa can rebuild a more stable immune brake against environmental antigens.

Treg upTolerance gainBrake restoredLower-relapse support
03

Threshold Reset

Pollen Allergy

Resetting NALT so mild exposure no longer triggers maximal reaction

Many flare events occur not because exposure is truly massive, but because nasal-associated lymphoid tissue has already begun interpreting very small stimuli as high-priority threats. The platform treats NALT as a threshold-rebuilding node so that short outdoor exposure or minor pollen fluctuations are less likely to trigger the full sneeze-itch-runny cascade.

NALTThreshold rebuildLess overreactionFewer seasonal flares
04

Neural Desensitization

Pollen Allergy

Reducing sensory hypersensitization to interrupt the neuroimmune reflex chain

Severe symptoms do not arise only from stronger inflammation, but from sensory nerves amplifying the signal. By reducing local neural hypersensitization, the platform aims to lessen itch, repeated sneezing, burning, and irritation so that the 'minor stimulus to major symptom' reflex chain becomes less easily triggered.

Higher sensory thresholdNeuroimmune de-noisingFewer sneezesLess itch
05

Barrier Repair

Pollen Allergy

Promoting tight-junction expression to reduce repeat allergen penetration

When the nasal barrier remains chronically fragile, pollen particles more easily penetrate and retrigger local recognition, reinforcing allergy over and over again. Beyond immune correction, the platform also supports epithelial tight-junction expression and mucosal integrity to reduce opportunities for allergen penetration and interrupt the cycle of repeated hypersensitization.

Tight junctionsBarrier repairLess penetrationRecurrence cycle break

Featured Indication Summary

Why pollen allergy is presented as a standalone feature

This page extends the featured card on the main screen and explains the lead indication with greater depth and structure.

Pollen allergy is isolated as a featured card because it showcases nearly the entire platform capability stack: upstream immune rebalancing, tolerance rebuilding, local threshold reset, neural de-noising, and barrier-integrity repair. In other words, it is not merely one example within rhinitis, but the most representative demonstration scenario for the nasal spray platform.
Back to Nasal Spray Research

Continue

Explore the three category-level disease mechanisms

Pollen allergy is the featured single-disease entry, while the remaining content has been organized into respiratory, cardiopulmonary-axis, and CNS categories.

Respiratory DiseasesCNS Diseases